High prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in HIV-1-infected patients in Hong Kong

Journal of Clinical Virology

Volumn 47, Issue 3, 2010, Pages 273-275

  Leung, P H M ^a   Chen, J H K ^b   Wong, K H ^c   Chan, K C ^c   Lam, H Y ^b   Cheng, V C C ^b   Yuen, K Y ^b   Yam, W C ^b  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

Enfuvirtide; Gp41; HAART; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ENFUVIRTIDE;

ARTICLE; DNA SEQUENCE; GENE MUTATION; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING TEST; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS GENOME; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HONG KONG; HUMANS; MUTATION, MISSENSE; PEPTIDE FRAGMENTS; PREVALENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 76449107981     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.01.002     Document Type: Article

References (19)

1. Chan D.C., Fass D., Berger J.M., and Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 (1997) 263-273
2. Derdeyn C.A., Decker J.M., Sfakianos J.N., Zhang Z., O'Brien W.A., Ratner L., et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 75 (2001) 8605-8614
3. Marcelin A.G., Reynes J., Yerly S., Ktorza N., Segondy M., Piot J.C., et al. Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS 18 (2004) 1340-1342
4. Carmona R., Perez-Alvarez L., Munoz M., Casado G., Delgado E., Sierra M., et al. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J Clin Virol 32 (2005) 248-253
5. Oliveira A.C., Martins A.N., Pires A.F., Arruda M.B., Tanuri A., Pereira H.S., et al. Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B. C, and F isolates from Brazilian patients failing HAART. AIDS Res Hum Retroviruses 25 (2009) 193-198
6. Xu L., Pozniak A., Wildfire A., Stanfield-Oakley S.A., Mosier S.M., Ratcliffe D., et al. Emergence and evolution of Enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 49 (2005) 1113-1119
7. Chen J.H., Wong K.H., Chan K., Lam H.Y., Lee S.S., Li P., et al. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping. J Clin Virol 39 (2007) 125-131
8. Yam W.C., Chen J.H.K., Wong K.H., Chan K., Cheng V.C.C., Lam H.Y., et al. Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong. J Clin Virol 35 (2006) 454-457
9. Hue S., Clewley J.P., Cane P.A., and Pillay D. HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy. AIDS 18 5 (2004) 719-728
10. Kaye M., Chibo D., and Birch C. Phylogenetic investigation of transmission pathways of drug-resistant HIV-1 utilizing pol sequences derived from resistance genotyping. J Acq Immun Def Synd 49 1 (2008) 9-16
11. Sen S., Tripathy S.P., Sahni A.K., Gupta R.M., Kapila K., Chopra G.S., et al. Human immunodeficiency virus type 1 gp 41 mutations in proviral DNA among antiretroviral treatment-naive individuals from India. AIDS Res Hum Retroviruses 25 (2009) 521-523
12. Hanna L. T-20: first of a new class of anti-HIV drugs. BETA 12 (1999) 7-8
13. Rimsky L.T., Shugars D.C., and Matthews T.J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 72 (1998) 986-993
14. Greenberg M.L., and Cammack N. Resistance to Enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54 (2004) 333-340
15. Kinomoto M., Yokoyama M., Sato H., Kojima A., Kurata T., Ikuta K., et al. Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor. J Virol 79 (2005) 5996-6004
16. Chinnadurai R., Munch J., and Kirchhoff F. Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors. AIDS 19 (2005) 1401-1405
17. Cilliers T., Patience T., Pillay C., Papathanasopoulos M., and Morris L. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses 20 (2004) 477-482
18. Whitcomb J.M., Huang W., Fransen S., Wrin T., Paxinos E., and Toma J. Analysis of baseline Enfuvirtide (T20) susceptibility and co-receptor tropism in two-phase III study populations. Proceedings of the 10th conference on retroviruses and opportunistic infections. Boston, MA (2003) abstract no. 557
19. Melby T., Sista P., Demasi R., Kirkland T., Roberts N., Salgo M., et al. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to Enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 22 (2006) 375-385